每周股票复盘：祥生医疗（688358）H1营收2.36亿，净利降14.32%

Core Viewpoint - The company, Xiangsheng Medical, has experienced a decline in revenue and net profit in the first half of 2025, while continuing to invest in research and development for innovative ultrasound technologies [1][4]. Financial Performance - For the first half of 2025, the company reported revenue of 236.15 million yuan, a year-on-year decrease of 4.61% - The net profit attributable to shareholders was 69.70 million yuan, down 14.32% year-on-year - The net profit after deducting non-recurring items was 63.83 million yuan, a decline of 14.10% year-on-year [1][4]. Research and Development - The company invested 37.61 million yuan in research and development, accounting for 15.93% of its revenue - The workforce includes 178 R&D personnel, representing 34.30% of the total staff - Ongoing projects include the development of "I+ cardiac ultrasound," "I+ obstetric ultrasound," "I+ animal ultrasound," and "I+ ultrasound scanning robots" [1][4]. Product Development - The company launched the "I+ Robot Scanning" series, integrating visual recognition, precise robotic control, and AI-assisted screening systems - The breast artificial intelligence ultrasound robot has received a medical device testing report, featuring a touchscreen, electric examination bed, six-degree-of-freedom robotic arm, automatic image transmission, and AI-assisted reading capabilities - A partnership with the Gates Foundation was established in July 2025 to jointly develop intelligent obstetric and breast ultrasound screening equipment [2]. Corporate Announcements - Xiangsheng Medical will participate in a collective performance briefing for the medical device industry on September 17, 2025, with key personnel attending [3]. - The company plans to hold its first extraordinary general meeting of 2025 to discuss the cancellation of the supervisory board and amendments to the Articles of Association, with voting conducted both on-site and online [3][4].